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Toll-liknende reseptor-mediert inflammasjon i 
keratinocytter 
 
Gjennom arbeidet i denne avhandlingen har vi ønsket å finne mer ut av hvordan 
hudcellen selv setter i gang reparasjonsmekanismer etter ytre påvirkning, gjennom 
aktivering av hudcellens eget medfødte immunforsvar. Vi har hatt fokus på Toll-
liknende reseptorer (TLR), som er en særlig viktig del av dette immunforsvaret 
 
Det medfødte immunforsvaret gjenkjenner molekyler som evolusjonsmessig har 
som fellesnevner at de er assosierte med fare for organismen. Både fremmede 
molekyler fra mikrober og egne molekyler som varsler om skade kan gjenkjennes 
av det medfødte immunforsvaret. Aktivering av det medfødte immunsystemet 
setter i gang betennelsesreaksjoner. For å iverksette en effektiv 
betennelsesreaksjon, skiller aktiverte hudceller ut signalmolekyler, kalt cytokiner, 
som aktiverer flere andre celletyper og dessuten er med på å regulere 
betennelsesprosessens videre forløp 
 
Vi begynte arbeidet med å analysere cytokinprofiler i sårvæske fra akutte sår. I 
tillegg så vi på hvordan celler i et sårmiljø reagerte på stimulering med ulike TLR-
ligander og betennelsesfremmende cytokiner som er tilstede ved akutt betennelse. 
Analysene involverte i tillegg til hudceller også endotelceller (blodkarceller), 
fibroblaster (bindevevsceller), monocytter og nøytrofile ganulocytter (hvite 
blodceller).  
Et hovedfunn var at hudceller er særs følsomme for en syntetisk TLR3-ligand, 
polyI:C. Denne liganden er en analog av dobbeltrådet RNA, som man blant annet 
finner i enkelte virus. Stimulering med polyI:C utløste kraftige produksjon og 
frigjøring av de fleste av de 27 molekylære mediatorer vi undersøkte for. Øvrige 
sentrale TLR-ligander utløste liten eller ingen frigjøring av disse signalmolekylene 
fra hudceller. 
Dette funnet la grunnlaget for de videre studiene vi har gjort i denne avhandlingen, 
hvor vi forsøkte å finne mer ut av hvorfor hudceller er så følsomme for polyI:C, og 
hvordan polyI:C-stimulering fører til frigjøring av signalmolekyler viktige for 
igangsetting av betennelsesreaksjon. 
 
Vi gikk videre med å karakterisere hvordan polyI:C stimulering virker så å si 
utelukkende gjennom TLR3-reseptoren, til tross for at det finnes andre potensielle 
reseptorer og signaleringsmekanismer for denne liganden. Vi fant videre at TLR3-
stimulering førte til en dose-respons- avhengig celledød og samtidig frigjøring av 
det sentrale cytokinet CXCL-8. Celledød kan skje på ulike måter, og vi har 
beskrevet morfologiske karakteristika som gjorde det vanskelig å klassifisere 
celledøden som apoptose eller nekrose. Vi spekulerte i muligheten for at denne 
celledøden kunne passe med en tredje kategori; pyroptose. Dette er en type 
programmert celledød som karakteriseres av caspase-1 aktivering, men ikke de 
apoptotiske caspasene -8, -9 og -3/7. Vi fant også at stimulering med polyI:C 
sammen med en annen nukleinsyre beskyttet mot både toksisitet og inflammatorisk 
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respons. Denne effekten kunne vi tilskrive utkonkurrering av reseptor-mediert 
opptak av polyI:C i cellen. 
 
I det siste arbeidet rettet vi fokus på hvordan TLR3-responser er avhengige av 
caspase-4-aktivering. Caspase-4 er et protein som inngår i programmert celledød 
og i inflammasjon. Vi fant at TLR3-stimulering i hudceller førte til en kraftig 
aktivering av gener assosiert med betennelsesprosesser, herunder proformen av det 
viktige cytokinet interleukin-1β og bestanddeler i andre medfødte 
immunforsvarssystemer (NLRP3 og caspase-1). Ved å blokkere caspase-4, 
blokkerte vi både frigjøring av IL-1β og celledød. Caspase-1-hemming blokkerte 
også for IL-1β-frigjøring, men mindre effektivt enn caspase-4-hemming. Dette 
plasserer caspase-4 oppstrøms for caspase-1 i kaskaden for IL-1β-frigjøring. 
Videre fant vi at spesifikk hemming av caspase-4, men ikke caspase-1, beskyttet 
mot celledød.  TLR3 stimulering førte også til en tidlig aktivering av både den 
inflammatoriske caspase-1 og de apoptotiske caspasene-8, -9 og -3/7. Denne typen 
celledød av keratinocytter involverer således mekanismer som man observerer 
både ved apoptose og pyroptose.   
 
Ny og viktig viten om det medfødte immunforsvaret publiseres så å si daglig. I 
denne avhandlingen har vi demonstrert nye mekanismer for hvordan hudcellen 
igangsetter betennelsesreaksjoner gjennom TLR3-aktivering.  
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Abbreviations 
 
ADP  Adenosine diphosphate 
AIM2  Absent in melanoma, gene #2 
ALR  AIM2-like receptor 
AMP  Antimicrobial peptides 
APAF1  Apoptotic protease activating factor 1 
ASC  Apoptosis-associated speck-like protein containing a CARD 
ATP  Adenisne triphosphate 
Bcl-2  B-cell lymphoma 2 
BIR  Baculoviral inhibitory repeat 
CARD  Caspase recruitment Domain 
CD  Cluster of differentiation  
CIITA  Class II, major histocompatibility complex, transactivator 
CpG Cytosine followed by Guanosine with phosphatediester backbone 
of DNA   
CLR  C-type lectin receptor 
CNS  Central nervous system 
CTLD  C-type lectin domain 
CXCL-8 CXC chemokine-8 (previously IL-8) 
DAI  DNA dependent activator of IFN-regulatory factors 
DAMP  Damage associated molecular pattern 
DC  Dendritic cell 
DC-SIGN Dendritic cell-specific intercellular adhesion molecule-3-grabbing 
non-integrin 
DHX9 Human DEAH (Asp-Glu-Ala-His) box polypeptide 9 (an RNA 
helicase) 
DHX36  RNA helicase associated with AU-rich element 
DISC Death-inducing signalling complex 
DNA   Deoxyribonucleic acid 
dsRNA  Double-stranded RNA 
EGF  Epidermal growth factor 
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ER  Endoplasmic reticulum 
FGF  Fibroblast growth factor 
G-CSF  Granulocyte colony stimulating factor 
GM-CSF Granulocyte-macrophage colony stimulating factor 
hBD  Human β-defensin 
hToll  Human Toll-homologue 
HMGB1 High mobility group box 1 
ICAM-1 Intercellular Adhesion Molecule 1 
IFN  Interferon 
IL  Interleukin 
IL-1RA Interleukin-1 receptor antagonist 
iNOS  Inducible nitric oxide synthase 
IP-10  Interferon-inducible protein 10 
IRAK4  Interleukin-1 receptor-associated kinase 4 
IFI16  Gamma-interferon-inducible protein 16 
IRF  Interferon regulatory factor 
LPS  Lipopolysaccaride 
LRR  Leucine-rich repeat 
LRRFIP1 Leucine-rich repeat-containing protein 
LTA  Lipoteichoic acid 
MAL  MyD88 adaptor like (also named TIRAP) 
MAPK  Mitogen-activated protein kinases 
MC  Mast cell 
MCP-1  Monocyte chemotactic protein 1 
MDA5  Melanoma differentiation-associated gene 5 
MHC  Major histocompatibility complex 
Mincle  Macrophage inducible C-type lectin 
MIP-1β  Macrophage inflammatory protein-1β 
MMP  Matrix metalloproteinase 
mRNA  Messenger RNA 
MyD88  Myeloid differentiation factor-88 
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NACHT Abbreviation from combining NAIP, CIITA, HET-E, and TP1 
domains 
NAIP  Neuronal apoptosis inhibitory protein 
NF-κB  Nuclear factor kappa-light chain enhancer of activated B-cells 
NOD  Nucleotide binding oligomerization domain 
NLR  NOD-like receptor 
NLRC  NOD-like receptor with a caspase recruiting domain 
NLRP3  NOD-like receptor family, pyrin domain containing 3 
NLRX  NOD-like receptor family x 
NK-cell Natural killer-cell 
ODN  Oligodeoxynucleotide 
PAMP  Pathogen-associated molecular pattern 
PDGF  Platelet-derived growth factor 
PolyI:C  Polyinosinic acid:polycytidylic acid 
PYD  Pyrin-containing domain 
PYHIN  Pyrin and HIN200 domain-containing protein 
PRR  Pathogen recognition receptor 
RANTES Regulated on activation normal T-cell expressed 
RIG-I  Retinoic acid inducible gene-I 
RLR  RIG-I-like receptor 
RNA  Ribonucleic acid 
ROS  Reactive oxygen species 
Src  Sarcoma tyrosine kinase 
STAND Signal transduction ATPases with numerous domains 
STING  Stimulator of IFN genes 
Syk  Spleen tyrosine kinase 
ssRNA  Single-stranded RNA 
TBK1/IKKi Tank binding kinase 1/I-kappa-B kinase inducible 
TGF  Transforming growth factor 
Th-cell  T-helper cell 
TIR  Toll-/IL-1 receptor 
TLR  Toll-like receptor 
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TNF  Tumor necrosis factor 
TNFR  TNF receptor 
TRAF  TNF receptor associated factor 
TRAM  TRIF-related adapter molecule 
TRIF  TIR-domain-containing adapter protein inducing IFNβ 
TSLP  Thymic stromal lymphopoietin 
UPR  Unfolded protein response 
UV  Ultraviolet 
VCAM-1 Vascular cell adhesion protein 1 
VEGF  Vascular endothelial growth factor 
VISA  Virus-induced signalling adaptor 
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1 Introduction 
1.1 The immune system 
 
The human body is under constant challenge from various physical, chemical and 
microbial agents. A highly developed system of biological structures and processes 
composes the immune system that protects the human body from disease. The 
immune system must detect a wide variety of agents, and also distinguish them 
from the organism's own healthy tissue. Another important role of the immune 
system is to identify and eliminate cancer cells.  
 
The human microbial defence system can be regarded as consisting of three levels: 
(i) anatomical and physiological barriers; (ii) innate immunity; and (iii) adaptive 
immunity (Figure 1). The immune system protects organisms from infection with 
layered defences of increasing specificity. The first line of resistance consists of 
physical barriers such as skin and mucous membranes that prevents pathogens 
from entering the organism. If a pathogen breaches these barriers, an immediate, 
but non-specific innate immune response will be triggered by cell associated or 
secreted pattern recognition receptors. Should pathogens evade or survive these 
primary innate responses, the more elaborate adaptive immune system will be 
alarmed by the innate response. The adaptive immune system adapts its response 
during an infection to improve its recognition of the pathogen. This improved 
response is then retained after the pathogen has been eliminated, and allows the 
adaptive immune system to mount faster and stronger attacks next time this 
pathogen is encountered. 
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Figure 1. Three levels of human defence against infection. 
The human microbial defence system can be viewed as consisting of three levels: 
(1) anatomical and physiological barriers; (2) innate immunity; and (3) adaptive 
immunity. Failure in any of these systems will greatly increase susceptibility to 
infection. NLRs, nucleotide oligomerisation domain (NOD)-like receptors; TLRs, 
toll-like receptors. 
 
 
1.2  Pattern recognition receptors 
 
Despite being referred to as non-specific, the innate immune system holds 
substantial specificity to conserved molecular patterns in various microorganisms, 
known as pathogen-associated molecular patterns (PAMPs). Receptors to these 
patterns are called pattern recognition receptors (PRRs) (1). Upon PAMP 
recognition, PRRs initiate series of signalling programs that execute the first line of 
host defensive responses necessary for killing infectious microbes. In addition, 
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PRR signalling simultaneously induces maturation of dendritic cells (DCs), which 
is responsible for alerting induction of the second line of host defence, so-called 
adaptive immunity (2). The PRRs are also activated by damaged endogenous 
components from damaged or dying cells, recognizing damage-associated 
molecular patterns (DAMPs). As the inflammatory response induced in response to 
DAMPs is similar to that observed during microbial infection, certain PRRs are 
also involved in the induction of sterile inflammation. DAMPs and PAMPs may 
occupy the same or neighbouring binding sites on TLRs. There is also evidence 
that DAMPs require different co-receptors and accessory molecules to PAMPs (3). 
It has been postulated that feedback between PAMPs and DAMPs via overlapping 
receptors may form an important connection between infection and inflammatory 
disease reactivation or intensification (4).  
 
Intact microbial pathogens are usually composed of a number of PAMPs, which 
activate multiple PRRs. Moreover, different PRRs may recognize the same PAMP. 
At least five major classes of cell associated PRRs have been identified to date. 
They include transmembrane Toll-like receptors (TLRs), which are located at the 
extracellular surface or within endosomes. C-type lectin receptors are also 
membrane bound and characterized by the presence of a carbohydrate-binding 
domain. Of the cytoplasmic PRRs, there are three families: Nod-like-receptors 
(NLRs), retinoic acid-inducible gene (RIG)-I-like receptors (RLRs), and DNA-
sensors (5). In addition, numerous secreted PRRs exist; hereunder complement 
factors, ficolins, pentraxins and C-reactive protein. Activation of these PRRs can 
trigger the complement cascade, leading to opsonisation and phagocytosis. The 
secreted PRRs will not be discussed further in this thesis. 
 
1.2.1 Toll-like receptors 
 
Toll-like receptors (TLRs) were the first PRRs to be identified, and are also the 
most studied sub-group of PRRs. They receive their name from their similarity to 
the protein coded by the Toll gene identified in Drosophila in 1985 by Christiane 
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Nüsslein-Volhard. The gene in question, when mutated, makes the Drosophila flies 
look unusual, or “weird”. The researchers were so surprised that they 
spontaneously shouted out in German "Das ist ja toll!" which translates as "That's 
great!" (6). Subsequently, the same receptor was described as important in 
resistance to fungal infections in Drosophila (7). The first reported human Toll-like 
receptor was described by Nomura and colleagues in 1994 (8). A human 
homologue (hToll) was suggested to be involved in activation of NF-κB and 
induction of proinflammatory cytokines (7), later to be recognized as a receptor 
critical for cellular activation induced by the gram-negative cell wall component 
lipopolysaccharide (LPS) (9). 
  
The TLRs are the best characterized and recognize a wide range of PAMPs (10-
12). TLRs are transmembrane proteins and comprise an ectodomain, which 
contains leucine-rich repeats that mediate the recognition of ligands, a 
transmembrane region, and cytosolic Toll-IL-1 receptor (TIR) domains that 
activate downstream signalling pathways. They are expressed either on the cell 
surface or associated with intracellular vesicles. To date, thirteen mammalian TLRs 
have been identified; in human ten functional TLRs are found. Each TLR detects 
distinct PAMPs derived from viruses, bacteria, mycobacteria, fungi, and parasites. 
These include lipoproteins (recognized by TLR1, TLR2, and TLR6), double-
stranded (ds) RNA (TLR3), lipopolysaccharide (LPS) (TLR4), flagellin (TLR5), 
single-stranded (ss) RNA (TLR7 and TLR8), and DNA (TLR9) (2). The ligand for 
TLR10 is not known, but is believed to cooperate with TLR2 in the sensing of 
microbes and fungi through a different signalling function from TLR2 subfamily 
members (13).  
 
TLR1, TLR2, TLR4, TLR5, and TLR6 are localized on the cell surface and largely 
recognize microbial membrane components. TLR3, TLR7, TLR8, and TLR9 are 
expressed within intracellular vesicles such as the endoplasmic reticulum, 
endosomes, lysosomes, and endolysosomes (14). The proper cellular localization 
of TLRs is thought to be important for ligand accessibility, the maintenance of 
tolerance to self molecules such as nucleic acids and downstream signal 
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transduction (15). For instance, TLR3 and TLR7 localise in the same intracellular 
compartments often found adjacent to phagosomes containing apoptotic bodies, 
suggesting that TLR3 and 7 can be triggered by nucleic acids from apoptotic cells 
(16). 
 
Upon recognition, either as homodimers or heterodimers, with their respective 
ligands, TLRs recruit a specific set of adaptor molecules that harbours TIR 
domains, such as MyD88 and TRIF, and initiate downstream signalling events that 
lead to the secretion of inflammatory cytokines, type I IFN, chemokines, and 
antimicrobial peptides (15, 17). These responses cause recruitment of neutrophils, 
activation of macrophages, and induction of IFN-stimulated genes, resulting in 
direct killing of the infected pathogens. Moreover, activation of TLR signalling 
leads to maturation of DCs, contributing to the induction of adaptive immunity. 
 
Individual TLRs selectively recruit distinct adaptor molecules, providing specific 
immunological responses tailored to the infecting microbes (11). TLR3 and TLR4 
generate both type I interferon and inflammatory cytokine responses, while cell 
surface TLR1-TLR2, TLR2-TLR6 and TLR5 induce mainly inflammatory 
cytokines. These differences are explained by the signalling through different 
signalling pathways of the TIR domain–containing adaptor molecules, including 
MyD88, MAL (TIRAP), TRIF and TRAM.  
 
TLR signalling pathways can be largely classified as either MyD88-dependent 
pathways, which drive the induction of inflammatory cytokines, or TRIF-
dependent pathways, which are responsible for the induction of type I interferon as 
well as inflammatory cytokines (11, 17). The MyD88-dependent pathway is 
universally used by all TLRs except TLR3. Through this, transcription factor NF-
κB and mitogen-activated protein kinases (MAPKs) induce inflammatory 
cytokines. In contrast, TRIF is used by TLR3 and TLR4 and induces alternative 
pathways that lead to activation of the transcription factors IRF3 and NF-κB and 
the consequent induction of type I interferon and inflammatory cytokines. TLR7 
and TLR9 recruit MyD88 along with IRAK4 and TRAF6, which activate IRF5 and 
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NF-κB for inflammatory cytokine induction and IRF7 for type I interferon 
induction. TRAM and MAL function as sorting adaptors that recruit TRIF to TLR4 
and MyD88 to TLR2 and TLR4, respectively (2, 18).  
An overview of TLR-signalling is given in figure 2. 
 
(figure legend next page) 
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Figure 2. Toll-like-receptor signalling. 
Toll-like receptor signalling pathways result in activation of transcription of pro-
inflammatory cytokines. TLRs signal through two different pathways: the MyD88-
dependent pathway and the MyD88-independent/TRIF-dependent pathway. TLR1, 
2, 5, 6, 7, 8 and 9 signal through the MyD88-dependent pathway (→). TLR3 
signals through the TRIF-dependent pathway (→). TLR4 is special as it signals 
through both pathways. Activation of NFκB leads to transcription of pro-
inflammatory cytokines and chemokines, while activation of IRF3 and IRF7 induce 
transcription of type-I interferons. This schematic overview shows simplified 
sequential activation of proteins. 
 
1.2.2  C-type lectins 
 
The CLRs encompass a diverse family of proteins unified by the possession of at 
least one C-type lectin domain (CTLD), a structurally conserved motif that 
recognises an array of both endogenous and exogenous ligands. Similar to other 
PRRs, such as the Toll-like receptors (TLRs), CLRs are involved in host defence 
against pathogenic infection. In contrast to TLRs, which recognize various PAMPs 
such as lipopolysaccharides, proteoglycans and nucleic acids, CLRs mostly 
recognise carbohydrates on pathogens (19).  Fungal cell walls contain multiple 
types of carbohydrates, such as mannans, β-glucans and chitin. Therefore, CLRs 
play a central role in the recognition and shaping of immune responses to fungal 
pathogens. The collaboration of TLRs and CLRs together tailors the host immune 
responses in fungal infections (19). CLRs are commonly expressed on myeloid 
cells of the immune system, but are also expressed on mucosal epithelial cells 
where the host is in contact with the microbial flora and potential pathogens, e.g. 
the gut and respiratory tract. Some CLRs directly activate intracellular signalling 
cascades via intrinsic signalling motifs, such as Syk/CARD-pathways, while others 
make use of adaptor molecules to initiate signal transduction (20). CLR signalling 
cascades can act to promote, modulate or repress cytokine production in host cells, 
helping to determine the host immune response and outcome of infection (21).  
Examples of central CLRs are Dectin-1, Dectin-2, DC-SIGN, Mincle (macrophage 
inducible C-type lectin) and the mannose receptor. In addition, the collectins 
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comprise a group of soluble CLRs, all of which have been implicated in inducing 
or modulating cytokines in response to fungi.  
 
1.2.3  NOD-like receptors and inflammasomes 
 
NOD-like receptors (NLRs) is short for Nucleotide Oligomerization Domain 
receptors. 
This is a large family of PRRs that respond to various stimuli, including PAMPs, 
non-PAMP particles and cellular stresses (22, 23). Divergence in the mechanism of 
NLRs is also reflected by functions beyond pathogen recognition, as NLRs are 
involved in many different cellular processes (24). NLRs are found to play roles in 
signal transduction, cell death, development and reproduction, autophagy, 
autoimmune and inflammatory diseases (24). Still, the functions and signalling 
pathways of a large subset of NLRs remains obscure (25). 
 
NLRs belong to the signal transduction ATPases with numerous domains 
(STAND) subclade of the AAA-ATPase superfamily. They are characterized by a 
centrally located nucleotide-binding domain, a variable number of highly 
polymorphic C-terminal leucine-rich repeats (LRRs), and diverse N-termini 
(Figure 3). STAND proteins are molecular switches regulated via nucleotide 
binding. The ADP-bound form represents the resting “off” state. Upon recognition 
of endogenous or exogenous ligands, a conformational change allows ADP to be 
exchanged for ATP. This initiates either activation of NF-κB or MAP kinases to 
induce the production of inflammatory cytokines, or activate a multiprotein-
complex; the inflammasome (26). Inflammasomes can be reckoned as a subgroup 
of NLRs, although a member in the HIN200 family (AIM2) is also an 
inflammasome. Most of the inflammasomes contain a PYD-domain, in contrast to 
the NODs that contain a CARD-domain. The exception is NLRP1 that possesses 
both PYD- and CARD domains. The inflammasome initiates the proteolytic 
cleavage of various caspases resulting in the maturation and production of 
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inflammatory cytokines, such as IL-1β and IL-18, in addition to initiation of 
pyroptosis in macrophages (27).  
 
Fig 3. Structure of different Nod-like receptors. 
The conserved domains of NLR proteins are represented. N-terminal baculoviral 
inhibitory repeat (BIR) domain, caspase recruitment domain (CARD), pyrin 
domain (PYD), activation domain (AD), and undefined domains are specific to 
animals. 
 
The term inflammasome was also chosen to highlight structural and functional 
similarities with APAF1, a component in another well-known caspase-activating 
complex, the apoptosome, a molecular platform that triggers apoptosis. 
Inflammasomes are assembled after sensing a structurally diverse repertoire of 
PAMPs and DAMPs. The range of activation signals sensed by each protein is 
distinct, but may include overlapping signals (28).  
NLRP3, the best characterized inflammasome, is activated by a large variety of 
signals with strikingly structural diversity, including PAMPs, DAMPs and bacterial 
toxins (29-32), whereas the AIM2 (not belonging to NLRs, see DNA-sensors 
below) and NLRC4 inflammasomes are activated only by specific PAMPs, double-
stranded DNA (dsDNA) and specific bacterial proteins, respectively (33, 34). 
Several models have been proposed to explain how these signals are sensed. 
Mounting evidence now indicates a primordial role of the mitochondria in NLR 
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activation (35, 36). Two recent studies suggest that the NLRP3 inflammasome 
ultimately senses mitochondrial dysfunction and initiates inflammatory responses 
following specific forms of cellular stress through sensing of reactive oxygen 
species (ROS) (35, 37). It remains unclear what the ligand for NLRP3 is, but one 
possibility is this ligand is released from the ROS-generating damaged 
mitochondria.  Still, there are also other theories on direct and indirect recognition 
of activation signals of the inflammasome (28). Figur 4 illustrates the current view 
on NLRP3 inflammasome activation (38). 
Inflammasome activity needs to be tightly regulated by the host to avoid the excess 
production of cytokines or overt cell death. Regulation occurs at transcriptional and 
post-transcriptional levels. the expression of inflammasome sensors, in particular 
NLRP3, is relatively low in many cell types and requires a priming signal to be 
induced (39), alternative splicing of inflammasome components (40), subcellular 
location and trafficking of inflammasome components (41), and downregulation 
either through secreted factors or cell–cell interactions leading to transcriptional 
and post-transcriptional downregulation of inflammasome activity (42, 43). 
 
 
20
 
(figure legend next page) 
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Figure 4. Supposed mechanisms for NLRP3 activation. 
Three different models for activation of the NLRP3 inflammasome are prevailing 
(38):  
The channel model - Cellular stress or damage induced by DAMPs and PAMPs 
results in potassium efflux through pore formation. This potassium disturbance 
may activate the NLRP3 inflammasome directly or through allowing cytoplasmic 
entry of extracellular factors that are direct NLRP3 ligands.  
The lysosome rupture model - Lysosomal rupture due to organelle damage leads to 
cytoplasmic release of cathepsin B, which either directly or through cleaving an 
unidentified substrate induces activation of NLRP3.  
The ROS model - Both lysosomal damage and potassium efflux leads to 
mitochondrial dysfunction and the generation of ROS. The NLRP3 inflammasome 
is then triggered by one or several unknown intermediates, possibly originating 
from the mitochondrium. Mitophagy prevents further NLRP3 inflammasome 
activation by clearance of ROS-producing mitochondria. 
 
1.2.4  RIG-I-like receptors 
 
The RIG-I-like receptors (RLRs) family has three known members: retinoic acid-
inducible gene (RIG-I), melanoma differentiation-associated gene 5 (MDA5), and 
laboratory of genetics and physiology-2 (LGP2) (44). The RLRs recognize viral 
RNAs in the cytoplasm. RNA virus infection leads to the generation of dsRNA and 
RNAs with 5’-triphosphate ends in infected cells. Long dsRNA is not normally 
present in cells, and the 5’- ends of host RNAs are typically capped and sensed by 
RIG-I and MDA5. The role of LGP2 is still unclear, but it is suggested to play a 
regulatory role in RIG-I ⁄MDA5 signalling (45, 46). In response to detection of 
viral RNAs, RIG-I and MDA5 associate with an adapter protein designated virus-
induced signalling adapter (VISA) (47, 48). RLRs induce inflammatory cytokines 
and type I interferons, through NF-κB- and IRF3/7-pathways, respectively (49, 50). 
The inflammatory cytokines initiate and co-ordinate various innate immune 
responses through recruitment of professional immune cells (51, 52). The 
production of type I interferons induces an antiviral state by altering various 
cellular processes. This inhibits viral replication, induces apoptosis in infected 
cells, increases the lytic capacity of natural killer cells, up-regulates the expression 
of MHC class I molecules and activates various components of the adaptive 
immune response. 
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 1.2.5  DNA-sensors 
 
Just over the last few years, this class of PRRs has gained a growing number of 
members. Like the cytosolic RNA recognition pathways, cytosolic DNA 
recognition also leads ultimately to production of type I IFNs. What is clear is the 
essential role of the recently new player in the pathways, stimulator of IFN genes 
(STING) in cytosolic DNA sensing pathways. STING is detected in the 
endoplasmic reticulum (ER) and upon activation complexes with signalling 
components including TBK1, leading to phosphorylation of IRF-3 (53, 54) Much 
less clear is the mechanisms or receptors which act upstream of STING.  However, 
the signalling pathways downstream of DNA sensors are poorly characterized (55). 
Apart from the transcription factors nuclear factor (NF)-κB and IFN regulatory 
factor 3 (IRF3), strong evidence exists for a central role for TANK-binding kinase-
1 (TBK1) in addition to STING (56).  
The sensors display some selectivity in regards of cell type, the pathogens sensed, 
and the exact nature of the DNA ligand tested. However, current evidence renders 
it unlikely that these diverse sensors display differential selectivity for different 
types of DNA. Rather they may all simply sense cytosolic dsDNA in different cell 
types (56). Among the characterized DNA-sensors, we find DNA-dependent 
activator of IFN-regulatory factors (DAI), RNA polymerase III, leucine-rich repeat 
(LRR)-containing protein (LRRFIP1), DHX9 and DHX36 (55, 57).  
Another cytosolic DNA receptor, AIM2, forms an inflammasome with ASC to 
trigger caspase-1 activation (33, 58). Very recently, IFI16 has also been proposed 
to mediate inflammasome activation, in response to Kaposi's sarcoma-associated 
virus infection of endothelial cells (59). Interestingly, IFI16 is proposed to sense 
viral DNA in the nucleus, indicating that IFI16 may have alternative DNA sensing 
functions in the nucleus and the cytosol. Both AIM2 and IFI16 belong to a protein 
family termed the pyrin and HIN domain (PYHIN) family, of which there are four 
known human members. It is recently suggested the existence of a brand new 
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family of PRRs termed Aim2-like Receptors (ALRs), consisting of AIM2 and 
IFI16, and possibly other members of the PYHIN-family (60). 
 
A complete overview of PRR-signalling is shown in Figure 5. 
 
(figure legend next page) 
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Fig 5 Overview of PRR mediated signalling. 
Toll-like receptor (TLR) signalling. Plasma membrane-localized TLRs, such as 
TLR4, TLR5, TLR11, and TLR2 (TLR2 forms a heterodimer with TLR1 or TLR6 
to form a functional receptor complex) and endosomal-localized TLRs, such as 
TLR3, TLR7, and TLR9, activate TLR signalling pathways. All TLRs, except 
TLR3, recruit MyD88 and activate MyD88- dependent signalling. TLR1, 2, 4, and 
6 all recruit the additional adaptor molecule MAL for activation of MyD88. TLR3 
recruits TRIF and activates TRIF-dependent signalling. TLR4 relocates to 
endosomes after ligand binding, where it also activates TRIF-dependent signalling 
through an additional adaptor molecule, TRAM. MyD88-dependent signalling is 
initiated through the recruitment and activation of various signalling molecules, 
which in turn activate the IKK complex. The active IKK complex activates NF-κB 
subunits to initiate the transcription of inflammatory cytokine genes. TLR7 and 
TLR9 ligands induces MyD88-dependent type I interferon production through a 
direct interaction between MyD88 and IRF7 via IRAK family proteins and 
phosphorylated IRF7. Phosphorylated IRF7 translocates to the nucleus and initiates 
the transcription of type I interferons. In addition the TLR7 and TLR9-mediated 
signalling pathways activate NF-κB via an MyD88-dependent signalling pathway. 
TLR3 activate the TRIF-dependent signalling pathway through recruitment of 
TRIF to induce transcription of inflammatory cytokines and type I interferons 
through the IKK- complex and TBK1/IKKi, respectively, via the activation of NF-
κB and IRF3/IRF7. 
C-type lectins signalling. Recognition of carbohydrate ligands by C-type lectins 
activate intracellular signalling cascades such as Syk or Src-kinases, which in turn 
activates CARD-complexes, eventually leading to activation of NF-κB and 
subsequent secretion of proinflammatory cytokines.   
RIG-I-like receptor (RLR) signalling. Recognition of ligands by cytosolic sensors, 
such as RIG-I and MDA5, activates signalling through the mitochondria-localized 
adaptor protein VISA leading to the activation of NF-κB and IRF3/IRF7 through 
the IKK complex and TBK1/IKKi, respectively, which results in the production of 
inflammatory cytokines and type I interferons. LGP2, another member of the RLR 
family, regulates the RIG-I- and MDA5-mediated signalling pathways. 
Nod-like receptor (NLR) signalling. Recognition of ligands by NOD1 and NOD2 
initiates activation of NF-κB via the IKK complex. Another member of the NLR 
family constitutes the multi-protein complex termed the inflammasome. This is 
required for the maturation or activation of pro-IL-1 family cytokines to its 
bioactive IL-1 family cytokines. Activation of the inflammasome requires two 
steps: 1- NF-κB-dependent up-regulation of the pro-forms of the cytokine. 2- 
Conversion of the inactive form of the cytokine to a bioactive form by the 
inflammasome. 
Cytosolic DNA sensor-dependent signalling. DNA in the cytoplasm of cells are 
sensed by various cytosolic DNA sensors which activate NF-κB and IRF3/IRF7 via 
the IKK complex and TBK1/IKKi. Upon activation, the ER-localized protein 
STING complexes with TBK1 and IKK-complex. Recognition of DNA by AIM2 
and IFI16 also induces the maturation of proIL-1β to IL-1β through an 
inflammasome complex consisting of ASC and caspase-1. 
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1.3  The skin as an immune organ 
 
The skin is more than an immunologically inert anatomical barrier to the hostile 
exterior. An expedient architectural structure and cellular composition the skin 
provides protection from injury and infection.  
 
The skin consists of two layers, the epidermis and dermis. The epidermis is the 
surface layer, consisting of a keratinized, stratified and squamous epithelium that is 
under constant exposure to the outside. The epidermis consists mainly of 
keratinocytes in various stages of differentiation, in addition to a few skin antigen-
presenting cells, dendritic epidermal T-cells and pigment-producing melanocytes. 
Under the epidermis, the dermis is a connective tissue composed of structural 
collagen and elastic fibres, in addition to a mixture of other extracellular matrix 
protein. In contrast to the epidermis, the dermis consists of a large variety of cell 
types, including fibroblasts, macrophages, mast cells, T cells, and dendritic cells 
(DCs). The fibroblast is the main stromal cell in the dermis. Fibroblasts have 
highly specialized roles in conditioning the cellular and cytokine environment in 
areas of inflammation by virtue of the complex array of factors they express (61). 
If the epidermal barrier is disrupted, pathogens as well as allergens make contact 
with resident innate immune cells in the skin. DCs are professional antigen-
presenting cells, which are ideally located to detect any skin invading pathogen and 
allergen. DCs are a heterogeneous population of immune cells, which are thought 
to exert different functions depending on their origin, their state of activation and 
their location. In the skin, DC subsets are classified as Langerhans cells (epidermal 
DCs), resident dermal myeloid DCs, plasmacytoid DCs, and myeloid dermal 
inflammatory DCs (62). A major function of DCs is the initiation of adaptive 
immune responses, but the skin DCs are also involved in innate immune responses. 
Of particular interest is how TLR activation can instruct adaptive immune 
responses by inducing a Th-1 type immune response. Activation of TLRs on DCs 
can promote upregulation of co-stimulatory molecules that help promote 
interaction and stimulation of antigen specific T cells of the adaptive immune 
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response and induction of T helper 1 (Th-1) cell-mediated immune responses (63). 
Langerhans cells participate in mediating TLR responses, and seem particularly 
responsive to TLR2 and TLR 7/8 ligands.  DCs contribute to host defence against 
bacterial infection via IL-1R/MyD88 signalling in resident skin by neutrophil 
recruitment to localized Staphylococcus aureus infection in the skin. Also autocrine 
or paracrine activation of DCs or Langerhans cells by IL-1β is one of the suggested 
mechanisms leading to the control of bacterial skin infection (64). DC-derived IL-1 
and IL-23 are also involved in the promotion of IL-17 production in memory T- 
cells, which can contribute to the protection against certain bacteria (65).  Mast 
cells (MC) are for many regarded as the “allergy cell”. Still, a crucial role of MCs 
in innate host defence is today well established (66). For instance, activation of 
skin MCs is crucial for the induction of protective innate immune responses to skin 
infection with Pseudomonas aeruginosa (67). MCs also protects against infection 
with invasive group A Streptococcus, where skin MC-derived production of the 
anti-microbial peptide (AMP) cathelicidin is an essential mediator leading to 
bacterial killing and possibly also to enhanced recruitment of neutrophils to the site 
of infection (68). MCs are also capable of modulating long term inflammatory skin 
reactions to environmental danger signals such as UV-irradiation (69, 70). The 
epidermal melanocyte protects human skin against carcinogenic UV irradiation by 
providing melanin. Melanocytes also exhibit a variety of functions. For example, 
human melanocytes have the capacity to express HLA-DR, CD40 and adhesion 
molecules, such as ICAM-1 and VCAM-1(71) and various soluble mediators of 
inflammation such as IL-1β, IL-6 and CXCL-8 (72).  
 
1.4  Keratinocytes as immune cells 
 
Immunologists in general have tended to focus on leukocytes as the central cell of 
the immune response, but in skin the keratinocyte is an essential and 
underappreciated part of immunological function (73).  
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The epidermis is in constant contact with multiple microbes (1 million/cm2). 
Therefore, an important and difficult task is to ensure reliable immunosurveillance 
and efficient defence against pathogens, and also avoid excessive immune 
responses, which might result in auto-immunity and chronic inflammation (74). At 
this interface between self and non-self, microorganisms compete for the 
colonization of the surface. Keratinocytes are specialized in many ways to exert 
their crucial role as outpost of the innate defence system. Only the innermost, basal 
layer of epidermal cells has the capacity for DNA synthesis and mitosis. Triggered 
by still an unidentified signal, the process of terminal differentiation is initiated. 
After approximately six weeks, the now dead, flat, enucleated and keratin-filled 
corneocytes in the stratum corneum is shed from the surface of the epidermis. The 
entire epidermis and in particular the top layer of dead cells plays a role as the first 
barrier against the environment. In the upper layer of the epidermis the cells build a 
physical barrier, the stratum corneum, against penetration of microbes and 
allergens. The nucleated epidermis is tightly locked together by desmosomes and is 
embedded in a hydrophobic intercellular matrix (62). Damage signals mediated 
through PRRs activate keratinocytes to enhance the production of constitutively 
expressed AMPs and can additionally induce the production and secretion of other 
mediators. This enables optimal innate immune responses either directly or through 
interaction with other cells.  
 
Keratinocytes have been shown to express TLRs 1, 2, 3, 5, 6 and 9 (75-78), 
whereas there is more controversy about expression of TLR4 in cultured primary 
keratinocytes (77, 79). There is no constitutive expression of TLR7 or TLR8 in 
keratinocytes (75, 79). TLR2 activation (in concert with TLR1 or TLR6) in 
keratinocytes results in activation of NF-κB and subsequent production of 
chemokines, iNOS and matrix metalloproteinase-9 (76). Mimicking viral infection, 
activation of TLR3 by its ligand, dsRNA (poly I:C), on human keratinocytes 
induces production of CXCL-8, TNF, IL-18, and type I interferon, and the 
chemokines -9 and IP-10 (75, 79, 80). TLR5 activation in human keratinocytes by 
its ligand flagellin, results in production of TNF, CXCL-8, and the antimicrobial 
peptides human β-defensins 2 and 3 (hBD2 and hBD3) (75, 79, 81). TLR9 
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activation with oligodeoxynucleotides also induces several chemokines, promoting 
memory T-cell responses and production of type I interferon (79). AMPs are vital 
elements in skin defence, as they possess a broad spectrum of antimicrobial activity 
as evidenced by their ability to exhibit multifunctional roles in defending against 
pathogenic insult (73). They do not only directly interact with pathogens but also 
modulate host immune responses. Keratinocytes are the most important producers 
of AMPs in the skin, the synthesis mainly taking place in the stratum granulosum, 
packaged into lamellar bodies, and then transported to the stratum corneum (82). 
There are described more than ten different classes of AMPs originating from 
keratinocytes, among them different subsets of the two most important families 
defensins and cathelicidins (73).  
 
The physical barrier in the skin is mainly comprised by the stratum corneum and 
consists of protein-enriched cells and lipid-enriched intercellular domains. The 
nucleated epidermis also contributes to the barrier through tight, gap and adherens 
junctions, as well as through desmosomes and cytoskeletal elements.  
The chemical barrier exists through the presence of highly organized lipids, acids, 
hydrolytic enzymes in particular in the upper layers of the epidermis. Also, on the 
surface, the dry skin surface with low pH (around 5.0) is hostile to many 
microorganisms. In addition, the presence of non-pathogenic microorganisms on 
the epidermis surface also defends against pathogens by limiting nutritional 
availability and through chemical secretions (83). 
 
1.5  Programmed cell death in relation to 
inflammatory processes 
 
Timely cell death is essential in normal growth and development, but also 
important in host defence. Through activation of different PRRs, cell death can 
arise from within the cell itself, or from a variety of extracellular sources (84). 
When these receptors are triggered, cells can die in an immunogenic or non-
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physiological way and rapidly initiate host defence responses. Different types of 
programmed cell death can therefore lead to the extracellular release of molecules 
and structures that can potently induce the innate immune system (85). 
 
In a review from 1994, Emmanuel Farber concluded in a review paper “that there 
is no field of basic cell biology and cell pathology that is more confusing and more 
unintelligible than the area of apoptosis versus necrosis” (86), and this opinion still 
holds considerable support 18 years later (87). From previously being viewed as 
either apoptosis or necrosis, several other forms of programmed cell death are now 
described. Pyroptosis (88) and autophagic cell death (89) are considered to be the 
two other major forms of programmed cell death. In addition, NETosis (90), 
necroptosis (91), mitotic catastrophe (92), and lysosomal membrane 
permeabilization (93) are described as other forms of cell death. These latter forms 
of cell death will not be discussed here.   
Morphologically, apoptosis is associated with cell shrinkage, membrane blebbing, 
and chromatin condensation. It is a cell-intrinsic programmed suicide mechanism 
that results in the controlled breakdown of the cell into apoptotic bodies(89). 
Two main evolutionarily conserved protein families are involved in apoptosis, 
namely the Bcl-2 family of proteins, which control mitochondrial integrity (94) and 
the cysteinyl aspartate-specific proteases or caspases, which mediate the execution 
phase of apoptosis (95).  
 
Necrotic cell death is characterized by DNA and nuclear fragmentation, loss of cell 
volume, formation of cytoplasmic and membrane blebs, packaging of cellular 
contents and phosphatidylserine externalization. Apoptotic cells are rapidly 
removed by neighbouring phagocytes without causing inflammatory response (96). 
Necrosis has been considered an accidental and uncontrolled form of cell death 
lacking underlying signalling events, but it has become evident that in certain 
conditions, necrosis is the result of a strictly regulated interplay of signalling 
events, which are initiated by a diverse range of stimuli, including PRRs (97). 
Necrotic cells increase their volume and permeability, maintain the uncondensed 
DNA content, and lose their cellular contents including uric acid, adenine 
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triphosphate, purine metabolites, high-mobility group box 1 protein (HMGB-1), 
heat shock proteins among others, which activate immune cells (96). 
 
Autophagy is another programmed process that might culminate in cell death. It is 
considered a protective process induced under stress conditions by which cells 
engulf large portions of their own cytoplasm or damaged organelles. This pathway 
is essential for maintaining cell viability under starvation and stress conditions, 
through nutrient recycling and toxic metabolite degradation. However, too 
excessive autophagy culminates in a silent cell death (98).  
 
Pyroptosis is a programmed cell death that uniquely depends on the inflammatory 
caspase-1 activity. As a member of the inflammatory caspases, it is not involved in 
apoptotic cell death (88), and the apoptotic caspases usually do not contribute to 
pyroptosis (99). Active caspase-1 is believed to be a central executor of pyroptotic 
cell death and acts mainly by inducing the formation of discretely sized ion-
permeable pores in the plasma membrane (100). The resulting osmotic pressure 
leads to water influx, cell swelling and ultimately cell lysis. The inflammatory 
response following cleavage of the proinflammatory cytokines pro-IL-1β and pro-
IL-18 into their active forms is not required for the execution of cell death (101). 
Although caspase-1 activation is associated with an inflammatory response, it is 
still unclear whether it is directly linked to pyroptotic cell death (89). Cells dying 
by pyroptosis have biochemical and morphological features of both apoptotic and 
necrotic cells (88), with loss of mitochondrial membrane potential and plasma 
membrane integrity, release of cytoplasmic contents into the extracellular milieu as 
observed in necrosis. On the other hand, pyroptotic cells undergo DNA 
fragmentation and nuclear condensation, however without the oligonucleosomal 
fragmentation pattern characteristic of apoptosis (102).  
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1.6  Caspases in inflammation and cell death 
 
Caspases are proteases produced in cells as catalytically inactive zymogens and 
usually undergo proteolytic processing during activation (103). In addition to their 
central role in programmed cell death, caspases are involved in many other vital 
process, including differentiation, enucleation, pruning of axons and dendrites, 
sperm differentiation, immunity, compensatory proliferation, and even learning and 
memory (104). 
Caspases play central roles in initiating apoptosis and pyroptosis but are not 
involved in other programmed cell death pathways (87).  
 
Caspases are traditionally classified as “apoptotic” and “pro-inflammatory” (Figure 
6). 
The subsets of caspases that cleave substrates during apoptosis are known as 
effector caspases (caspase-3, -6, and -7). These are activated by the initiator 
caspases such as caspase-2, -8, -9 and -10 Initiators are further divided into 
caspases participating in the extrinsic (caspase-8 and -10) or intrinsic (caspase-9) 
apoptotic pathway (105).  
 
 
Figure 6. Caspase structure.  
Three major classes of caspases are presented. Class I: apoptosis effector caspases, 
class II: apoptosis initiator caspases, class III:  inflammatory caspases: The CARD, 
the DED, and the large (p20) and small (p10) catalytic subunits are indicated. The 
p20 subunits of the caspases discussed in this thesis are coloured 
 
. 
 
Activation of the different initiator caspases depends on the engagement and 
activation of platforms that integrate cellular signals, recruit initiator caspases via 
their death-fold domain, and promote dimerization of the caspases. These events 
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together lead to the formation of an active enzyme proficient enough to initiate 
specific signalling cascades (105). Examples of these platforms are death-inducing 
signalling complex (DISC) for caspase-8 and -10, the PIDDosome for caspase-2, 
and the apoptosome for caspase-9 (95). 
 
Executioner caspases are activated by cleavage of the catalytic domain. In contrast 
to the apoptotic caspases, initiator and effector functions have not been defined for 
the inflammatory caspases. This understanding is now challenged by new 
discoveries in keratinocytes (106). In addition to the already mentioned caspase-1, 
caspase-4 and caspase-5 are also reckoned as inflammatory caspases, though their 
functions are less well defined (87). Studies on the mouse caspase-11, the 
orthologue to human caspase-4 suggests that caspase-11 rather than caspase-1 may 
be the critical effector of deleterious inflammatory responses (107). In a recent 
publication on keratinocytes, it is shown that caspase-4 is required for activation of 
inflammasomes, and that the active site of caspase-4 is required for activation of 
caspase-1, the latter most likely represents a substrate of caspase-4 (106). 
  
A large number of proteins have been reported to be in vivo caspase substrates 
(108, 109), and the list of annotated caspase substrates continues to increase. Still, 
most candidates lack functional evidence linking cleavage to a role in apoptosis. 
Only by removing irrelevant “bystander” substrates from the list of caspase 
substrates, it will be possible to gain a more realistic understanding of how 
caspases drive apoptotic cell death.  
 
Another factor is that caspase substrate specificity overlaps. Commonly used 
caspase substrates and inhibitors lack the specificity required to monitor individual 
caspase activity (110). For instance, fluoromethylketone inhibitors exhibit no 
specificity towards different caspases even at low concentrations (111). In contrast, 
aldehyde inhibitor caspases shows a considerably higher specificity (110).  
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2. Aim of the study 
 
Innate immunity in keratinocytes is not only involved in the direct fight against 
pathogens but turns out to be crucial for many inflammatory processes centrally 
involved in dermatological diseases. We wanted to achieve a better understanding 
of how the keratinocyte functions as an important initiator of skin inflammation as 
a non-professional cell. 
 
Specifically, we sought to: 
 
o Determine the repertoire and sensitivity to Toll-like receptors in 
keratinocytes 
 
o Investigate how Toll-like receptor signalling in keratinocytes 
contributes to inflammation through characterization of inflammatory 
responses 
 
o Investigate toxic and inflammatory responses of Toll-like receptor 
ligands on keratinocytes, and to see if these responses can be limited 
by intervention 
 
o Describe new mechanisms of TLR mediated inflammation and cell 
death in keratinocytes 
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3. Summary of papers 
 
Paper I 
 
”Cellular sources and inducers of cytokines present in acute wound fluid” 
 
In this paper we quantified the levels of cytokines and growth factors in acute 
wound fluid, using a BioPlex cytokine 27-plex panel for: TNF-α, IFN-γ, IL-1β, IL-
1RA, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12p70, IL-13, IL-15, IL-17, 
MCP-1, IP-10, RANTES, MIP-1α, MIP-1β, G-CSF, GM-CSF, Eotaxin, FGF, 
VEGF and PDGF. 
To obtain an overview of the initial inflammatory response in the acute wound 
healing process, we collected wound fluid from surgical drains the first 
postoperative day after reduction mammoplasty. As little is published about the 
cellular sources of different cytokines and growth factors in acute wounds and the 
stimuli inducing them, we stimulated different cell types present in the acute 
wound bed to gather more information about this. The cell types we stimulated 
were keratinocytes, monocytes, fibroblasts, endothelial cells, granulocytes and 
monocytes. We stimulated the cells with the pro-inflammatory cytokines TNF, IL-
1β and IL-6 in addition to the anti-inflammatory IL-10. Also, we wanted to 
characterize the responses induced by the TLR-ligands pam3Cys (TLR2/TLR1), 
polyI:C (TLR3) and LPS (TLR4). Supernatants from the stimulated cells were also 
subjected to 27-plex BioPlex analyses. 
In wound fluid, we found highest levels of IL-6 and CXCL-8. The levels of the 
potent pro-inflammatory cytokine IL-1β were surprisingly low in wound fluid, 
while its negative regulator IL-1RA was present at much higher levels. IL-1β was 
the most potent inducer of signal molecule production in the cell types we 
stimulated. We therefore underscore the importance of strong regulation of IL-1β- 
signalling in our discussion.  
Furthermore, we found that all cytokines detected in wound fluid could also be 
determined in supernatant from at least one of the cell types we stimulated. 
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Each cell type showed characteristic patterns for sensitivity of ligands and 
production of signal molecules after stimulation. Keratinocytes in particular 
showed surprising sensitivity to the TLR3 ligand polyI:C, eliciting production of 
almost all cytokines we examined for.  
 
 
 
Paper II 
 
“Oligodeoxynucleotides inhibit TLR3 mediated cytotoxicity and CXCL8 release 
in keratinocytes” 
 
After the discovery of polyI:C as a strong inducer of cytokine production in Paper 
I, we wanted to investigate more closely the effects of polyI:C in keratinocytes. 
PolyI:C induced a TLR3-dependent release of the chemokine CXCL-8 that was 
preceded by secretion of cellular break-down products associated with cell 
necrosis. Morphological studies on the polyI:C mediated cytotoxicity showed  
mixed features of apoptosis and necrosis, making it difficult to classify what kind 
cell death polyI:C actually induces in keratinocytes. However, we speculate if IL-
1β dependent pyroptosis can be the right answer. This is a matter we follow in 
Paper III. 
Also, we show competitive uptake between oligodeoxynucleotides and polyI:C. 
Co-stimulation with these two nucleic acid structures inhibit both TLR3 dependent 
polyI:C induced cytokine production and cytotoxicity. 
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Paper III 
 
“Toll-like receptor-3 stimulation induces caspase-4 dependent inflammatory cell 
death in keratinocytes” 
 
The intriguing findings in Paper II of polyI:C induced inflammation and cell death, 
which we proposed to be a pyroptosis, called for further investigations. We 
addressed the involvement of inflammatory caspases in inflammation and cell 
death, through induction and processing of pro-IL-1β and activation of apoptotic 
caspases, respectively. Stimulation with the ligand polyI:C induced a TLR3 
dependent transcription and of pro-IL-1β, but also a dose-dependent cytotoxicity. 
Further processing of IL-1β into its cleaved bioactive form dependent on NLRP3 
or ASC was found to be minimal. IL-1β release could be inhibited using caspase-1- 
or caspase-4- inhibitors, the latter being a more potent inhibitor. Inhibiting caspase-
4 also abolished polyI:C induced cell toxicity, whereas caspase-1 did not. We 
suggest that caspase-4 acts upstream of caspase-1 and the inflammasome for 
processing of IL-1β, but independently of caspase-1 in cell death induction. We 
also showed that polyI:C stimulation induced a TLR3 dependent activation of 
caspases-8, -9 and -3. All together, we demonstrated in this paper that TLR3 
stimulation of keratinocytes induced an inflammatory cell death that also involves 
activation of both inflammatory and apoptotic caspases. This type of cell death is 
difficult to classify as pyroptotic, as that mode of programmed cell death is not 
supposed to involve apoptotic caspases. 
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4. Discussion 
4.1 Inflammation in the skin 
 
Inflammatory skin diseases cause considerable morbidity in patients, such as in the 
chronic and relapsing inflammatory skin disorders like psoriasis and atopic 
dermatitis. Inflammation is a protective means by the organism to restore a 
homeostatic state after disturbance by a harmful or unwanted stimulus. The term 
inflammation is consequently used for a broad range of conditions depending on 
the eliciting stimuli. Infections activate the innate immune system rapidly and 
induce an inflammatory response, initiating a defence against the invading 
pathogen. Tissue damage from laceration, contusion or sunburn also results in local 
and acute inflammation, thereby allowing an efficient tissue repair response. But as 
exemplified by the chronic, relapsing skin disorders, inflammation can also be 
undesirable. Such is the case when the immune system reacts to self, or when the 
inflammation enters chronic and destructive states. During the last decade, the 
innate immune system has been shown to play a central role in several 
inflammatory skin diseases and healing processes.  
 
4.2 Keratinocytes as innate immune cells in skin 
inflammatory disease  
 
Immunologists have tended to focus on leukocytes as the central cell of the 
immune response, but in skin the keratinocyte is an essential and underappreciated 
part of the immunological function (73). An important and difficult task for the 
epidermal cells is to ensure proper immunosurveillance and efficient defence 
against pathogens, and also avoid excessive immune responses, which might result 
in auto-immunity and chronic inflammation (74).  
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Keratinocytes are central skin sentinels that recognize foreign and dangerous 
agents, i.e. (PAMPs) of microbial origin and damage-associated molecular patterns 
(DAMPs), such as irritants and toxins, through Toll-like receptors (TLRs) and the 
inflammasome machinery. In Paper I and Paper II we demonstrate a particular 
sensitivity of keratinocytes to the viral dsRNA-mimic, polyI:C. TLR3, RIG-I, 
MDA5, and possibly IFN-inducible double-stranded RNA-activated protein kinase, 
can recognize dsRNA (112). TLR3 is located in endosomes and, in some types of 
cells, also on the cell surface, whereas the other three dsRNA sensors, RIG-I, 
MDA5 and protein kinase, are located in the cytosol (113). In Paper II and Paper 
III, we found that polyI:C induced inflammation and toxicity were TLR3-
dependent, indicating that the cytosolic sensing in keratinocytes does not play a 
vital role when stimulating with extracellular dsRNA.  
 
Keratinocytes produce an innate immune response to TLR-stimulation. In addition 
to induction of anti microbial peptide-production, keratinocytes secrete numerous 
cytokines, including IL-1, IL-6, IL-10, IL-18 and TNF (114). In Paper I, we 
showed that the cytokines IL-2, IL-9, IL-13 are also components in the 
armamentarium of the keratinocyte after TLR-stimulation. Of particular interest 
with regard to the skin in health and disease is the production of IL-1β by 
keratinocytes, as we focused on in Paper I and III, and this matter will be dealt 
with later.  
 
Keratinocytes are also important sources of chemokines and express chemokine 
receptors, and can modulate an immune response by attracting different cell types 
into the skin. By expressing CC-chemokine ligand 20 (CCL20), CXC-chemokine 
ligand 9 (CXCL9), CXCL10 and CXCL11 activated keratinocytes selectively 
attract effector T cells to the skin during diseases that are characterized by T cell 
infiltration, such as psoriasis (114). In Paper I, we also demonstrated that TLR3 
stimulation induces the CC-chemokine MIP-1β (also known as CCL4), a 
chemokine that in a recent paper appear to be pivotal for the skin recruitment of 
proinflammatory cells and clinical severity in psoriasis (115). 
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4.3 Receptor-mediated uptake of polyI:C and 
induction of TLR3-dependent  responses in 
keratinocytes  
 
In Paper II, we showed that uptake of polyI:C was inhibited by concomitant 
addition of oligodeoxynucleotides (ODNs) to the medium. A number of studies 
agree that oligonucleotides enter cells by receptor-mediated endocytosis because: 
uptake of oligonucleotides is a saturable process (116, 117), and oligonucleotides 
have been found in intracellular vesicles (117). PolyI:C has in one paper been 
demonstrated to enter the cell through a clathrin dependent endocytic pathway 
(118), whereas others suggest a noncaveolar/ clathrin-independent pathways for 
cellular uptake of oligonucleotides (119). However, the receptors that are 
responsible for cellular entry of oligonucleotides have not been identified, but 
many candidates exist.  
 
In an attempt to find specific receptors responsible for uptake of polyI:C or ODNs, 
we interfered with several receptors through either inhibition with different 
scavenger receptor antibodies (blocking antibodies for Scavenger receptor class A) 
or silencing using small interfering RNA siRNA for different scavenger receptor 
sequences (Macrophage scavenger receptor 1, Scavenger receptor class A member 
3, Scavenger receptor class B member 1 and 2, and Receptor for Advanced 
Glycation Endproducts). Unfortunately, we did not succeed in inhibiting polyI:C or 
ODNs in any of our experiments (data not shown). Our result thus support the 
current view that uptake of free nucleic acids occurs through different mechanisms.      
After endocytic entry, polyI:C will encounter TLR3, which is normally located in 
acidic endosomes. The luminal ectodomain encounters dsRNA and promote the 
formation of a dimer of the two lateral surfaces of the receptor. Then, the two C-
termini are brought in close proximity for signal transduction. This again promotes 
recruitment of the adapter molecule TRIF to the cytoplasmic domain of TLR3, 
initiating signalling pathways that activate downstream transcription factors (120).  
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The length of dsRNA fragments needed to induce a TLR3 mediated immune 
response is debated, though. There seems to be considerable variation among 
different cell types, but the dsRNA length required for signal transduction is in 
general suggested to be at least 40 to 50 base pairs (121). However, others have 
shown that the dsRNA length threshold varies considerably among cell types, and 
that synthetic small interfering dsRNA duplexes as short as 23 base pairs can 
induce a potent IFN response through TLR3 (122). Off-target effects in siRNA 
experiments may therefore be a problem in one cell type and not in another (122).  
 
An interesting question is why keratinocytes are so sensitive to TLR3-ligands. 
Infection in the skin with any of the eight members of dsRNA familiy viruses (123) 
is a rather infrequent problem. Other sources of viral dsRNA can be derived from 
the replication of other RNA and DNA viruses which produce dsRNA as a by-
product of replication (124). TLR3 is mostly thought of as an intracellular receptor, 
resident on the membranes of endosomal vesicles. However, weak cell surface 
TLR3- expression has been demonstrated in keratinocytes (125). Viral infection of 
epithelial cells appears to induce localisation of TLR3 to the cell surface where it 
serves to sensitize or “prime” the cells to better recognise and respond to 
subsequent viral challenge (126).  
However, multiple evidences indicate that the receptor must serve other purposes 
than merely recognizing limited types of viruses. 
 
Proofs of TLR3 as an endogenous sensor of cell damage appeared with the 
discovery of RNA sensing from necrotic cells and tissue, whereas RNA from 
apoptotic cells did not mediate TLR3 signalling (127, 128). Lai et al found that 
RNA from necrotic cells triggers TLR3 in undamaged cells, leading to a local 
release of proinflammatory cytokines (129). Cell necrosis is a common feature at 
the wound edge. In wild type mice, the mRNA level and protein expression of 
TLR3 is significantly upregulated in wounded skin (130). TLR3-deficient mice 
produce significantly less IL-6 and TNF at wound edges compared to wild-type 
controls, concluding that TLR3 activation is required for normal inflammation after 
injury (129).  
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TLR3 can be activated though the presence of secondary structures, such as 
hairpins, which have dsRNA regions in endogenous host single-stranded mRNA 
(127). Nucleoside modifications, such as methylation, can further regulate the 
immunogenicity of the RNA. There is reduced signalling of common mammalian 
modifications of RNA through TLR3 compared to minimally modified viral 
nucleic acids (131). It is also interesting how a well-orchestrated degradation of 
cellular RNA occurs in apoptotic cells, but not in necrotic cells (131). This 
suggests that sudden damage to self during necrosis can lead to release of RNA 
with limited modification. This may induce a TLR3 response, whereas an apoptotic 
cell death elicits little inflammation through TLR3 due to a more planned RNA 
degradation.   
 
4.4  Skin diseases with suggested TLR3 involvement 
 
Atopic dermatitis is the most common chronic inflammatory skin disease of early 
childhood. It is characterized by dry skin, a cutaneous barrier defect, enhanced 
allergen priming, susceptibility to cutaneous bacterial colonization and infection 
(especially Staphylococcus aureus infection), and cutaneous inflammation driven 
by type 2 helper T (Th2) cells (132).  
TLR3 mediated signalling has been suggested to play a role in maintaining an 
inflammatory environment in the skin through driving the thymic stromal 
lymphopoietin (TSLP) production in keratinocytes. TSLP is highly expressed by 
keratinocytes in the lesions of atopic dermatitis patients and in allergic diseases 
also involving the skin (133). The barrier defect in atopic dermatitis may lead to 
subsequent tissue damage with release of endogenous RNA as initiator of TLR3 
sensing (113). The TLR3–NF-κB axis triggers production of TSLP (134), which 
can actively drive a Th2 cytokine response, potentially through effects on DCs, 
granulocytes, natural killer cells and CD4+ T cells, inhibiting the Th1 responses 
that normally are induced by TLR-stimulation (135). Deficiency or aberrant 
expression of the filaggrin protein, essential for the regulation of epidermal 
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homeostasis is strongly associated with atopic dermatitis (136). In an in vitro 
model, TLSP release is highly increased in filaggrin knockdown after TLR3 
stimulation. This suggests that reduced filaggrin levels may influence innate 
immune responses via TLR stimuli and may contribute to the pathogenesis of 
inflammatory skin disease via TSLP expression (137) 
 
Injury to the skin such as surgery, cuts, abrasions, and burns have been 
documented as initiation sites for progressive depigmentation. Intercellular cell 
adhesion molecules (ICAM-1) are involved in cell–cell interactions of leukocytes 
and target cells, and thus play an important part in the initiation of immunologic 
and inflammatory reactions (138). As ICAM-1 expression has been observed in 
melanocytes around active vitiligo patches, it has been hypothesized that the 
excessive expression of ICAM-1 in melanocytes makes these cells a target for 
infiltrating T lymphocytes (139, 140). A novel publication points at RNA released 
from necrotic keratinocytes as an endogenous TLR3 ligand for the stimulation of 
ICAM-1 and other proinflammatory gene expression in human melanocytes (141). 
TLR3 might thus be involved in the pathogenesis of local depigmentation 
following skin physical trauma. 
 
In patients with systemic sclerosis, or scleroderma, resident and infiltrating cells in 
the dermis secrete soluble mediators, such as TGF-β, that activate fibroblasts. 
Production of large amounts inflammatory cytokines and chemokines initiate skin 
fibrosis and chronic inflammation. Patients with scleroderma have identified 
dysregulation of type I interferon (IFN) pathways. Type I IFN has no apparent role 
in regulating TGF-β activity in the skin, but has been shown to increase TLR3 
expression on human dermal fibroblasts, resulting in enhanced TLR3-induced IL-
6- and TGF-β production (142, 143). Induction of TLR3 expression and signalling 
may thus increase the inflammatory potential of dermal fibroblasts. 
 
Altogether, TLR3 activation is probably a mechanism of detecting injury and 
maintaining homeostasis. 
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4.5  Interleukin-1 and inflammasomes in keratinocytes 
and skin associated diseases 
 
We have had a focus on interleukin (IL)-1 in paper I and III. As a highly active 
and pleiotropic pro-inflammatory cytokine, IL-1 plays an important role in an 
efficient tissue repair response against trauma or infection (144, 145). Biological 
responses of IL-1 are mediated by the IL-1 receptor type I (IL-1RI), which is 
ubiquitously expressed. The prominent role of IL-1 signalling for inflammation is 
demonstrated through IL-1RI and TLRs sharing the same cytoplasmic signalling 
domain, the Toll/interleukin-1 receptor (TIR) domain (144). Agonists of IL-1RI are 
IL-1α and -β, which are both initially expressed with an amino-terminal 
propeptide. Pro-IL-1β does not bind or activate IL-1RI, whereas pro-IL-1α has the 
same biological activity as mature IL-1α (144).  
 
Expression of IL-1 is regulated at the transcriptional level by nuclear factor κB 
(NF-κB). Pro-IL-1α and -β lack a signal peptide for protein secretion and thus 
leave the cell through one or several poorly understood mechanisms, called 
unconventional protein secretion (146). This protein secretion is independent of the 
classical endoplasmic reticulum (ER)/Golgi pathway. Caspase-1 activity is 
required for the activation of pro IL-1β in cytosol, but also for the unconventional 
secretion of pro IL-1α and of many other proteins involved in inflammation, repair 
and cytoprotection (147). Activity of IL-1 is also regulated by the secreted IL-1 
receptor antagonist (IL-1Ra), which prevents binding of IL-1α and - β to IL-1RI 
through blockade of the receptor. 
Keratinocytes are known as major producers of IL-1α, and mechanisms of 
induction as well as biologic effects of IL-1α are well described (144, 148-150). 
Activation and secretion of IL-1β is more complex, but keratinocytes express all 
inflammasome proteins in vitro and most likely also in vivo (148, 151). Recent 
papers have demonstrated involvement of inflammasome activation in 
keratinocytes upon UVB-irradiation (106, 148, 152). The question whether 
keratinocytes are able to activate caspase-1 was previously a matter of controversy 
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(153), but in line with previous findings we establish keratinocytes as major 
producers of IL-1β in the skin (148). However, we conclude in Paper III that 
TLR3-stimulation does not induce a powerful activation of the NLRP3-
inflammasome, as very little of the induced pro-IL-1β is processed to cleaved IL-
1β. This suggests that TLR3 induced cell death with subsequent release of pro-IL-
1β plays a role in local inflammation through other mechanisms.  
 
As shown in Paper I, TLR3-stimulation induces release of numerous cytokines, 
with the primary task of recruiting leukocytes. Epidermal injury, independent of 
infiltrating inflammatory cells, generates prominent chemotactic activity toward 
neutrophils in injured skin because of CXCL-8 production (154). Neutrophils are 
short-lived cells, dying within hours after emigration, and release of unprocessed 
IL-1β from intracellular stores is expected. As a consequence, extracellularly 
processing of IL-1β is reported for a variety of proteases of leucocyte origin. 
Proteinase-3 from neutrophils provides an alternative mechanism for the cleavage 
and release of IL-1β (155). Other proteases, such as elastase, matrix 
metalloproteinase 9, chymases and granzyme A released by neutrophils and mast 
cells in an acute wound bed process IL-1β extracellularly (144, 156, 157).  
 
IL-1β activity is important in inflammatory and allergic skin diseases such as 
psoriasis or contact dermatitis, demonstrating the importance of IL-1β in the skin 
(158, 159). As non-professional immune cells, keratinocytes orchestrate infiltrating 
T cells in inflammatory skin conditions through IL-1β production (148, 160). In 
Paper I, we emphasize the role of IL-1β as a powerful inducer of many cytokines 
and growth factors in acute wound healing. Levels of IL-1β have been shown to 
correlate with the important chemokine CXCL-8 (145), a chemokine we focused 
on in Paper II. We also support the view of keratinocytes as potentially important 
producers of IL-1β, as we have found considerable release of the cytokine after 
polyI:C stimulation in both Paper I and III.  
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IL-1β-mediated diseases are often called “auto-inflammatory” and the dominant 
finding is the release of the active form of IL-1β driven by endogenous molecules 
(161). Aberrant activity of the IL-1β and the inflammasomes is involved in the 
pathogenesis of many diseases, including skin diseases (144). Inhibition of the 
activity of IL-1β through IL-1Ra (anakinra), soluble receptors for IL-1 (rilonacept) 
and human mAbs to IL-1β (canakinumab and Xoma 052) have been used as 
successful treatment to neutralize IL-1β specifically in many auto-inflammatory 
conditions, including the ones discussed below (161).  
 
Cryopyrin-associated periodic syndrome is associated with mutations in the 
NLRP3 gene. These mutations result in constitutive activation of the NLRP3 
inflammasome and, therefore, in uncontrolled activity of IL-1β. This demonstrates 
the importance of NLRP3 and of IL-1β in humans. The clinical findings are 
recurrent urticaria-like rashes, typical periodic fever episodes, bone/joint 
manifestations, and CNS involvement (162).  
 
Deficiency in IL-1Ra due to homozygous mutations in this gene causes life-
threatening auto-inflammation, affecting mainly the skin (severe pustulosis and 
ichthyosiform lesions) and the bones, similar to symptoms of patients suffering 
from cryopyrin-associated periodic syndrome (74).  
 
The triad of sterile pyogenic arthritis, pyoderma gangrenosum and acne is known 
by the acronym of PAPA syndrome. It is a rare autosomal dominant disease of 
early onset, caused by mutations in the proline serine threonine phosphatase-
interacting protein 1 (163). The molecular mechanism behind PAPA syndrome is 
still unknown, but the mutant protein is suspected to inhibit the anti-inflammatory 
activity of pyrin, leading to elevated IL-1β levels (164, 165).  
 
Cytophagic histiocytic panniculitis is characterized by daily high spiking fevers 
and severe panniculitis. Patients may have a rapidly fatal disease course, a longer 
disease course with intermittent remissions and exacerbations for many years prior 
to death, or a nonfatal acute or intermittent course responsive to treatment. A 
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number of genetic mutations central to cytotoxic T cell and NK cell function can 
lead to this syndrome characterized by massive secretion of cytokines, including 
IL-1β, produced by activated macrophages (166).  
 
IL-1β plays a role in the carciogenesis, tumour angiogenesis, development and 
invasiveness in experimental tumour models (167-170). Melanoma cells produce 
numerous cytokines associated with invasiveness and aggressiveness (171). These 
include IL-6, CXCL1–3, CXCL-8, CCL5 (RANTES) and monocyte chemotactic 
protein-1 (MCP-1, also known as CCL2). All of these cytokines can be regulated 
by the active (secreted) form of IL-1β (172), suggesting that IL-1β plays a critical 
role in melanoma pathogenesis (173). Therefore, as preclinical evidence provides 
ample support for reducing IL-1 activity in treating human metastatic disease, 
treatment with agents blocking the IL-1β effects may have a place in treating 
metastatic malignant melanoma. 
4.6  TLR3-mediated cell death and caspase activation 
in keratinocytes 
 
The traditional dichotomous classification of caspases as “apoptotic” and “pro-
inflammatory” is still prevailing. Nevertheless, most apoptotic candidates (caspase-
2, -3, -6, -7, -8, -9, and -10) have at least one non-apoptotic role attributed to them 
(174). Similarly, typical “non-apoptotic” members such as caspase-1, -4, and -5 
have been proposed to induce pyroptosis (175, 176). The only truly remaining non-
apoptotic human candidate may therefore be caspase-14, a mediator in keratinocyte 
differentiation (177). 
 
In Paper III we demonstrate that polyI:C induces both pro-caspase-1 and pro-IL-
1β mRNA. Caspase-1 is required for the activation of pro-IL-1β. The requirement 
of caspase-4 in inflammation has until recently been poorly characterized (23, 
178). Our findings are in line with a parallel finding, showing that caspase-4 is 
required for activation of caspase-1, the latter most likely representing a substrate 
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of caspase-4 (106). We further demonstrated that polyI:C activated caspase-4, and 
that this induced both the extrinsic and intrinsic apoptotic pathways through 
caspase-8 and caspase-9 activation, respectively. In caspase-inhibitor experiments, 
we observed that polyI:C induced cytotoxicity was abolished when caspase-4 was 
inhibited. We therefore conclude that caspase-4 plays an important role in both 
inflammation and cell death in keratinocytes.  
 
Human caspase-4 and -5 are poorly characterized (178, 179). Both caspases have 
been suggested as functional orthologues of the murine caspase-11 (26, 180, 181), 
but caspase-4 has also been suggested as the murine caspase-12 homolog (182, 
183). Recently, caspase-11 has been shown to trigger caspase-1-independent 
macrophage death and caspase-1-dependent IL-1β production in response to a 
subset of inflammasome activators in mice (107). This suggests that caspase-11 
rather than caspase-1 may be the critical effector of deleterious inflammatory 
responses in mice (107).  
 
Through which TLR3-dependent mechanisms polyI:C induces caspase-4 activation 
remains to be unravelled. There is staggering evidence to suggest that caspase-4 
mediated cell death is connected with death ER-stress. First, caspase-4 is localized 
to the ER (182). Second, caspase-4 closely associates with several essential 
proteins in ER stress-induced cell death pathways, such as glucose-regulated 
protein 78 and inositol-requiring enzyme 1 (184), APAF1, a protein involved in 
death protease mediated cell death (185), TRAF6, a member of the TNF receptor-
associated factor (186) and CARD-only protein, a regulator of procaspase-1 (187). 
Third, different strategies for knocking down caspase-4 expression in with siRNA, 
introduction of caspase-4 antisense nucleotides, expression of inactive caspase-4 
and micro-injections of caspase-4 antibodies have all abolished ER stress-induced 
cell death in different cell types (188-192). Fourth, caspase-4-inhibitors have 
effectively blocked ER-induced cell death melanoma cells (193), lung and 
esophageal cells (194), retinal pigment epithelial cells (195) and neuroblastoma 
cells (196). Fifth, overexpression of caspase-4 in COS-7 cells induces activation of 
caspase-3 and -9 (197). 
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Factors that perturb ER function and contribute to the development of ER stress 
include increases in protein synthesis or protein misfolding rates that exceed the 
capacity of protein chaperones, alterations in calcium stores in the ER lumen, 
oxidative stress and disturbances to the redox balance in the ER lumen (198). In 
Paper I, we observed that polyI:C was a powerful inductor of almost all 
chemokines, cytokines and growth factors we measured for in a high throughput 
protein based luminex assay. Also in Paper III, we observed in precipitate from 
supernatant and in lysate for Western blotting that polyI:C stimulated cells released 
considerably higher amounts of protein than un-stimulated cells. Therefore, we 
suggest that TLR3-mediated increase in protein synthesis is a candidate mechanism 
for induction of ER stress.  
 
Secreted and membrane proteins fold and mature in the lumen of the ER before 
they are delivered to other compartments in the endomembrane system, displayed 
on the cell surface, or released extracellularly. A collection of signalling pathways 
are collectively termed the unfolded protein response (UPR). This mechanism 
monitors conditions in the ER through sensing an insufficiency in the ER’s protein-
folding capacity. If the status of the ER lumen is hampered, this is communicated 
back to gene expression programs in the nucleus. This transcriptional control is 
accompanied by mechanisms that transiently decrease the flux of proteins entering 
the ER (147, 199). In conditions of prolonged stress, the goal of the UPR changes 
from being one that promotes cellular survival to one that commits the cell to a 
pathway of apoptosis. Juxtaposition of ER and mitochondria promotes inter-
organelle crosstalk and mediates cell death. The apoptotic crosstalk between the 
two organelles is tightly controlled by the anti-apoptotic mitochondrial Bcl-2 
protein family. Initiation of signalling pathways converge on Bcl-2, favouring a 
pro-apoptotic drive at the mitochondria by proteins that cause mitochondrial 
damage, cytochrome c release and eventual caspase 3 activation (200). 
Interestingly, both caspase 8-mediated extrinsic pathway and caspase 
9/mitochondria-mediated intrinsic pathway has being demonstrated in TLR3 
mediated cell death (201, 202). 
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Human caspase-4 activation has recently been shown to be the initiating event in 
the caspase-dependent apoptotic pathway (203, 204). Overexpression of caspase-4 
induces cleavage of caspase-9 and caspase-3 without releasing cytochrome-c from 
the mitochondria (197, 204). Cleavage of caspase-4 is not affected by the 
overexpression of Bcl-2, which prevents signal transduction on the mitochondria. 
In addition, the overexpression of caspase-4 does not induce efflux of cytochrome-
c from mitochondria to cytosol (197). Caspase-4 can thus activate downstream 
caspases independently of mitochondrial apoptotic signalling, but downstream 
events from caspase-4 are not fully understood.  Based on what we know about 
caspase-4 dependent cell death, we propose a model for how this may come about 
in Figure 6.  
 
We therefore suggest that the traditional classification of caspases probably needs 
revisal based on our and others recent discoveries regarding functions of 
particularly caspase-4 (107, 195, 203, 204).  
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Figure 6. Possible mechanism for TLR3 induced caspase-4 dependent cell 
death. 
TLR3 stimulation leads to transcription of several proinflammatory genes. Proteins 
are translocated into the ER lumen in an unfolded state and require protein 
chaperones and catalysts of protein folding to attain their final appropriate 
conformation. Processes that prevent accumulation of unfolded proteins in the ER 
lumen are triggered, as the capacity of the ER as a regulator for protein folding and 
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secretion is exceeded. Unable to adapt sufficiently to alterations in client protein-
folding load in the ER lumen, changes in intralumenal calcium are induced. 
Mitochondrial- dependent and independent pathways are engaged. Caspase- 4 is an 
ER-associated proximal effector in the caspase activation cascade that activates 
procaspase-9 to cleave procaspase-3, the primary executioner of cell death. 
Caspase-4 also activates procaspase-8, which also in turn activates caspase-3. 
Mitochondrial ROS can be generated as a result of ER stress-induced Ca+2 release 
and depolarization of the inner mitochondrial membrane. Thus, oxidative stress in 
association of unresolved ER stress also contributes to pathways of cell death.  
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5. Concluding remarks 
 
The keratinocyte has an active role in local immune responses in the skin. 
Providing the first-line innate responses, keratinocytes contribute to the adaptive 
immune responses that can be associated with clinical disease. Keratinocytes can 
also enhance and shape subsequent inflammation in response to stimuli and 
promote specific types of immune bias. 
 
In the present study, we have revealed new aspects of how inflammation is 
regulated by innate immune receptors. In particular TLR3 expressed by 
keratinocytes is a potent mediator of inflammation through release of 
conventionally secreted cytokines and chemokines. In addition, coincidental TLR3 
mediated cell death in keratinocytes contributes to considerable release of the pro-
form of the highly proinflammatory cytokine interleukin-1β. This can contribute to 
further local inflammation through extracellular processing of inflammatory cells 
attracted to a site of injury. TLR3-dependent toxicity and proinflammatory 
responses were inhibited by concomitant stimulation with oligodeoxynucleotides. 
In cases of unwanted inflammation, such as in UV-induced damage, treatment with 
oligodeoxynucleotides is a possible therapeutic agent.  
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